Diabetes (Type 1)

About Diabetes (Type 1) Clinical Trials (Click to Open)

Join Clinical Trials for Diabetes Type 1

General Purpose:

Clinical Trials for Diabetes Type 1Managing Diabetes Type 1 is a life-long responsibility. Clinical trials for Diabetes Type 1 are therefore attempting to improve the quality of life of those dealing with this autoimmune disease.

Studies of youth populations intend to learn more about the complications of diabetes and investigate the effects of care and medications. Many studies set forth to gain an improved understanding of how this disease develops in those who are at-risk.

Within this at-risk population, other studies are attempting to either delay or ideally prevent the development of Type 1 Diabetes through the use of different interventions. Some clinical trials will even have participants undergo transplantations of the cells that have been destroyed by their immune system, and will then provide medications that inhibit their immune systems from once again destroying these cells.

The intention will be to determine the combined benefit of such intervention on insulin independence, which will ideally increase. If your body does not produce insulin and you must revolve your life around your daily diabetes management, then these clinical trials should benefit you and may be worth the investment of your time.

What will Clinical Trials for Diabetes Type 1 be like?

Your eligibility must first be evaluated during a screening phase to ensure that you are the right fit for the trial. The goal of these trials is to improve the quality of life of those with Type I Diabetes Clinical TrialsType 1 Diabetes, so inclusion criteria are intended to provide this benefit and avoid wasting your time.

They are also put in place to avoid any risk from detrimental pharmaceutical interactions with another medication that you are taking. The researchers will therefore ask you to provide a very detailed medical history. In preventative trials, participants will be given a screening for the presence of diabetes-related autoantibodies, which involves drawing a small blood sample.

Further blood testing may also be conducted to confirm eligibility. Interventional trials will assess your body’s inability to produce insulin and determine any history with severe hypoglycemia.

Typical Trial Protocol for Clinical trials for Diabetes Type 1:

If the main interventional method being tested is a new pharmaceutical, you will be randomly assigned to a group that either receives a varying dose of the treatment or a placebo.

Clinical Trials for Diabetes Type 1If islet transplantation is part of the treatment, participants will wait for a preparation of islets to become available and will then be randomly assigned to one of the groups that receive medications at different time points during the transplantation process. Though there is a chance that the transplant may fail, participants in these trials may be eligible to undergo another.

To evaluate this intervention, participants will be asked to visit for follow up physical examinations, blood tests, and urine collection. While participating in these interventional studies, you will receive care and your insulin will be managed, though you may be unable to participate in other studies to avoid detrimental interactions between trial treatments.

Studies aimed at enhancing the understanding of diabetes will request many questionnaires about an individual’s health and medical conditions, with follow up physical examinations, clinical tests, and interviews.

These may include blood and urine tests, blood pressure, and measurements of height, weight, etc. These studies will require minimal effort in comparison to interventional studies, but will help to provide a large database of information for researchers to draw conclusions from to help improve the lives of those afflicted with diabetes.

Preventative trials will randomly assign participants to a group that will either receive the potential preventative treatment or a placebo. Follow up visits will require blood and other clinical tests depending on the specific trial.

Since relatives of people with type 1 Diabetes are 10 to 15 times more likely to develop this autoimmune disease, these clinical trials are beneficial to you as they may be able to determine your estimated risk for disease development. You will also be providing critical insight into how this disease develops in at-risk individuals.

Suggested Search Terms:

Type 1 Diabetes in Youth, Type 1 Diabetes and Insulin Resistance, Prevention of Type 1 Diabetes, Islet Transplantation for Type 1 Diabetes, Blood Sugar and Type 1 Diabetes

Current Search Term Used: “Diabetes Type 1″



Group Education Curriculum for Older Teens With Type 1 Diabetes


Condition:   Type 1 Diabetes Mellitus
Intervention:   Behavioral: Intervention
Sponsor:   Boston Children’s Hospital
Not yet recruiting - verified May 2017


Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes


Condition:   Type 1 Diabetes
Interventions:   Drug: Ergocalciferol;   Other: Placebo
Sponsor:   University of Massachusetts, Worcester
Not yet recruiting - verified April 2017


Use of Continuous Glucose Monitoring System With Intensive Feedback in Adolescents With Poorly Controlled Type 1 Diabetes


Condition:   Type 1 Diabetes
Interventions:   Device: CGMS Device;   Other: No Device
Sponsor:   New York University School of Medicine
Enrolling by invitation - verified January 2017


Sleep, Coping and Executive Functioning in Youth With Type 1 Diabetes


Condition:   Diabetes Mellitus, Type 1
Intervention:   Other: No intervention
Sponsor:   Yale University
Enrolling by invitation - verified September 2016


Study the Feasibility of Permanent Use of inControl for the Treatment of Type 1 Diabetes


Condition:   Type 1 Diabetes
Intervention:   Device: insulin pump to inControl AP platform
Sponsors:   University Hospital, Montpellier;   MEDBIOMED, Montpellier, France;   Jaeb Center for Health Research;   University of Virginia
Recruiting - verified November 2016


A Phase 2, Multicentre, Randomized, Double-blind, Placebo-controlled Study in Patients With New-onset Type 1 Diabetes


Condition:   Diabetes Mellitus, Insulin-Dependent
Interventions:   Drug: Ladarixin;   Drug: Placebo
Sponsor:   Dompé Farmaceutici S.p.A
Recruiting - verified September 2016


Gene-virus Interactions Implicated in Type 1 Diabetes


Condition:   Type 1 Diabetes
Intervention:   Genetic: Enterovirus vaccination
Sponsor:   Hospices Civils de Lyon
Not yet recruiting - verified June 2016


Insulin Requirement for Pure-protein Meal in Children With Type 1 Diabetes on Insulin Pumps.


Condition:   Diabetes type1
Interventions:   Drug: Insulin glulisine;   Drug: Insulin aspart;   Drug: Insulin lispro
Sponsor:   Medical University of Warsaw
Recruiting - verified January 2016


Modulation of STAT3 Signaling With Siltuximab in Type 1 Diabetes


Condition:   Type 1 Diabetes
Intervention:   Drug: Siltuximab
Sponsors:   Carla Greembaum, MD;   Janssen Research & Development, LLC
Active, not recruiting - verified March 2017


Young With Diabetes Type 1 - Test of an mHealth App


Condition:   Diabetes Mellitus, Type 1
Intervention:   Device: Young with Diabetes - app
Sponsors:   Nordsjaellands Hospital;   Herlev Hospital;   Steno Diabetes Center;   Zealand University Hospital
Completed - verified December 2015


Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults


Condition:   Type 1 Diabetes
Interventions:   Drug: Victoza®;   Drug: Placebo
Sponsors:   University of Oulu;   Oulu University Hospital;   Tampere University Hospital;   Turku University Hospital
Enrolling by invitation - verified September 2016


The Safety and Efficacy of Dapagliflozin Therapy in Combination With Insulin in Japanese Subjects With Type 1 Diabetes Mellitus (T1DM)


Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: Dapagliflozin 5 mg;   Drug: Dapagliflozin 10mg
Sponsor:   AstraZeneca
Active, not recruiting - verified April 2017


Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus


Condition:   Type 1 Diabetes Mellitus
Interventions:   Drug: Pramlintide acetate;   Drug: Placebo;   Drug: Lispro insulin U-100;   Drug: Regular insulin U-100
Sponsors:   AstraZeneca;   Juvenile Diabetes Research Foundation
Completed - verified September 2016


Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus


Condition:   Diabetes Mellitus, Type 1
Interventions:   Biological: Albiglutide weekly injection;   Biological: Placebo weekly injection;   Biological: Insulin
Sponsor:   GlaxoSmithKline
Active, not recruiting - verified May 2017


Pancreas Volume in Preclinical Type 1 Diabetes


Condition:   Type 1 Diabetes
Intervention:   Procedure: MRI, US, and blood samples
Sponsor:   University of Florida
Recruiting - verified April 2017


ATG-GCSF in New Onset Type 1 Diabetes


Condition:   Diabetes Mellitus, Type 1
Interventions:   Drug: Anti-Thymocyte Globulin (ATG);   Drug: Granulocyte colony stimulating factor (GCSF);   Drug: Placebo (for ATG);   Drug: Placebo (for GCSF)
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   National Center for Research Resources (NCRR);   Juvenile Diabetes Research Foundation;   American Diabetes Association;   Sanofi;   The Leona M. and Harry B. Helmsley Charitable Trust;   Amgen
Active, not recruiting - verified July 2016


Telemedicine for Adolescents With Insulin-dependent Diabetes


Condition:   Type 1 Diabetes
Interventions:   Other: Telemedicine;   Other: Control
Sponsor:   Texas Tech University Health Sciences Center
Active, not recruiting - verified April 2017


Clinical Trial of Efficiency and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus


Condition:   Type I Diabetes Mellitus
Interventions:   Drug: Subetta;   Drug: Placebo
Sponsor:   Materia Medica Holding
Completed - verified December 2016


Islet Allotransplantation in Type 1 Diabetes


Condition:   Type 1 Diabetes
Intervention:   Drug: Human Pancreatic Islets
Sponsor:   Ohio State University
Enrolling by invitation - verified February 2017


Imaging of Type 1 Diabetes Progression


Condition:   Type 1 Diabetes
Intervention:   Drug: ferumoxytol
Sponsors:   Jason Gaglia;   National Institute of Allergy and Infectious Diseases (NIAID);   Harvard Medical School
Active, not recruiting - verified April 2017


Diabetes Care Management Compared to Standard Diabetes Care in Adolescents and Young Adults With Type 1 Diabetes


Condition:   Type 1 Diabetes
Intervention:   Other: Transition Coordinator
Sponsors:   University of Western Ontario, Canada;   Juvenile Diabetes Research Foundation
Active, not recruiting - verified December 2016


Comparison Between GLP 1 Analogues and DPP 4 Inhibitors in Type 1 Diabetes Mellitus


Condition:   Type 1 Diabetes
Interventions:   Drug: Insulin;   Drug: Sitagliptin;   Drug: Exenatide
Sponsor:   Command Hospital, India
Completed - verified July 2016


Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes


Condition:   Type 1 Diabetes
Interventions:   Device: Closed loop;   Device: Home glucose monitoring;   Device: Insulin pump;   Device: Continuous glucose monitor
Sponsor:   Jaeb Center for Health Research
Terminated - verified November 2016


Trial of Intranasal Insulin in Children and Young Adults at Risk of Type 1 Diabetes


Condition:   Type 1 Diabetes
Interventions:   Biological: Intranasal insulin;   Other: Placebo
Sponsor:   Melbourne Health
Active, not recruiting - verified May 2015


Improving Metabolic Assessments in Type 1 Diabetes Mellitus Clinical Trials


Condition:   Diabetes Mellitus, Type 1
Interventions:   Procedure: Mixed Meal Tolerance Test;   Procedure: Glucagon Stimulation Test
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Juvenile Diabetes Research Foundation;   National Center for Research Resources (NCRR)
Completed - verified June 2016

Refine Your Search Advanced Search